David Grainger, PhD
Jim Huntington, PhD
Z Factor was founded in 2014 to identify and develop therapeutic agents to treat alpha-1-antitrypsin deficiency, or AATD, a common genetic disorder where a single mistake in the DNA encoding the protein alpha-1-antrypsin causes both liver and lung disease.
The lead product candidate, ZF874, is a novel compound that acts as a molecular patch for the faulty protein, allowing it to fold correctly, thereby simultaneously relieving the liver burden of polymer accumulation and providing fully-functional Z-A1AT in the circulation to protect the lungs.
We are currently conducting the Phase 1 Part B ZF-0101 study evaluating the safety, tolerability and pharmacokinetics of ZF874 in PiXZ subjects.